This is a routine, small-scale disposition consistent with prior months' activity and not indicative of material concern. Traders should monitor for any acceleration in volume or changes in tone from management, but no immediate reaction is warranted.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 14 $27.32entry
- T+1 · 7mo ago +11.35%α +10.57% · $30.42
- T+5 · 7mo ago +5.34%α +3.95% · $28.78
- T+20 · 6mo ago +8.82%α +2.53% · $29.73
- T+60 · 4mo ago +6.00%α −2.52% · $28.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
David Rodman, an officer of Mineralys Therapeutics, filed a Form 144 to notify intent to sell up to 14,058 shares of common stock, following a series of prior cashless exercises of stock options. This proposed sale is part of an ongoing pattern of insider transactions over the past several months.
Key Facts
- David Rodman, an officer, filed Form 144 to sell up to 14,058 shares.
- The shares are from a broker-assisted cashless exercise of employee stock options on April 13, 2026.
- Rodman has conducted multiple similar transactions between January and April 2026, totaling over 77,000 shares sold.
- No unusual timing relative to earnings or major catalysts is indicated.
- Market cap is $2.2B; this sale represents a negligible portion of outstanding shares.
Financial Impact
Approximately $370,000 at recent prices (based on prior April 14 sale of 11,367 shares for $370,645), representing less than 0.1% of market cap.
Risk Factors
- Perception of insider selling if aggregated with prior transactions
- Potential downward pressure if sale is executed rapidly
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001964306-26-000201 |
| Document: 0001964306-26-000201-index.html | 0001964306-26-000201 |
| Document: 0001964306-26-000201.txt | 0001964306-26-000201 |
Track record
35 reports on MLYS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 10 went positive at some point.
Filters
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
- Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
- Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers